London
He regularly advises on IPOs, direct listings, follow-ons, de-SPACs, reverse mergers and takeovers on UK, US and European stock exchanges, domestic and cross-border public and private M&A deals, venture capital, private and growth equity investments, debt financings, joint ventures, carve-outs, and restructurings, as well as on governance, disclosure, compliance and strategic advisory matters.
His broad industry experience includes working with clients in the AI and technology, healthcare and life sciences, logistics, retail, media, marketing, financial services, energy and natural resources sectors.
He was recently recognised in The Lawyer's Hot 100 2023, by Financial News as a Rising Star of Legal Services in Europe 2023 and Financial Times at its European Innovative Lawyer Awards 2023.
London
He regularly advises on IPOs, direct listings, follow-ons, de-SPACs, reverse mergers and takeovers on UK, US and European stock exchanges, domestic and cross-border public and private M&A deals, venture capital, private and growth equity investments, debt financings, joint ventures, carve-outs, and restructurings, as well as on governance, disclosure, compliance and strategic advisory matters.
His broad industry experience includes working with clients in the AI and technology, healthcare and life sciences, logistics, retail, media, marketing, financial services, energy and natural resources sectors.
He was recently recognised in The Lawyer's Hot 100 2023, by Financial News as a Rising Star of Legal Services in Europe 2023 and Financial Times at its European Innovative Lawyer Awards 2023.
Washington, D.C.
Washington, D.C.
Whitney advises clients on a variety of litigation, enforcement, and regulatory matters.
Washington, D.C.
Washington, D.C.
Whitney advises clients on a variety of litigation, enforcement, and regulatory matters.
Boston
Ashlie grew up in a family of restaurant franchisees, and she learned about the power of a strong trademark at a young age. This understanding led her to pursue a career in trademark and copyright law, and from her start as a trademark prosecution intern at Hewlett Packard Enterprise in law school, through her work in trademark and copyright litigation at Fish & Richardson P.C., her practice has always focused on assisting businesses with their intellectual property needs.
Ashlie’s practice at Orrick focuses on domestic and international trademark and copyright prosecution and counseling. She has experience assisting businesses ranging from small start-ups to multi-billion dollar corporations with trademark clearance, protection, and strategy. Additionally, Ashlie has extensive experience in intellectual property litigation in federal district courts and at the International Trade Commission. Because of her wide-range of experience, she brings to each matter a unique understanding of the intersection of copyright and trademark clearance and prosecution and enforcement and litigation.
Boston
Ashlie grew up in a family of restaurant franchisees, and she learned about the power of a strong trademark at a young age. This understanding led her to pursue a career in trademark and copyright law, and from her start as a trademark prosecution intern at Hewlett Packard Enterprise in law school, through her work in trademark and copyright litigation at Fish & Richardson P.C., her practice has always focused on assisting businesses with their intellectual property needs.
Ashlie’s practice at Orrick focuses on domestic and international trademark and copyright prosecution and counseling. She has experience assisting businesses ranging from small start-ups to multi-billion dollar corporations with trademark clearance, protection, and strategy. Additionally, Ashlie has extensive experience in intellectual property litigation in federal district courts and at the International Trade Commission. Because of her wide-range of experience, she brings to each matter a unique understanding of the intersection of copyright and trademark clearance and prosecution and enforcement and litigation.
New York
With a Ph.D. in biology from MIT and the Whitehead Institute, where she was a NSF fellow, Irena represents plaintiffs and defendants in their most complex pharmaceutical and biotech patent cases. Over the last 20 years, pharmaceutical and biotechnology innovators have relied on Irena again and again for cases involving small molecules, biologics, recombinant DNA technology, gene therapy, gene editing, manufacturing processes, formulations and drug-eluting medical devices, including numerous multi-billion dollar cases involving many of the world’s best-selling drugs.
Irena has significant experience in litigation under the Hatch-Waxman Act (ANDA and 505(b)(2) actions) and the Biologics Price Competition and Innovation Act (BPCIA), as well as inter partes review (IPR) proceedings, license disputes and matters with parallel ex-U.S. litigation and proceedings in foreign patent offices. Irena also helps life sciences companies and organizations develop the law in the most important cases for the biopharma industry. She has been principal counsel on numerous amicus briefs to the United States Supreme Court and the Federal Circuit in key biopharma cases.
For plaintiffs, Irena has successfully defended generic challenges to patents protecting blockbuster medical therapies, including multi-billion dollar cancer, antiviral, diabetes and anti-psychotic drugs, including recently obtaining attorneys’ fees in a hard-fought ANDA action. She also represents innovators in biosimilar litigation from its outset, including in some of the first cases under the BPCIA involving antibodies. Irena also represents clients in innovator vs innovator disputes. For defendants, she defeated a $530 million claim of patent infringement of a competitor’s biotech patent, obtaining dismissal of all claims and discovery sanctions against the patent owner. In another high-stakes case, she obtained summary judgment of noninfringement and exclusion of plaintiff’s experts under Daubert as well as a full award of attorneys’ fees. A registered patent attorney, Irena also handles inter partes review (IPR) proceedings. For patent owners, she has obtained denial of IPR for patents protecting blockbuster drugs and has leveraged IPR for defendants to obtain freedom to operate.
Irena also coordinates U.S. proceedings with parallel ex-U.S. litigation and proceedings in foreign patent offices, recently obtaining freedom to operate for a biotech innovator’s gene therapy. She provides strategic counseling in biologics and pharmaceuticals and advises clients on their IP portfolios and transactions. Irena also represents clients in high-stakes license disputes involving biotech patents, and, in a dispute concerning the use of a recombinant protein as an enzyme replacement therapy, obtained one of the largest settlement awards over the life of the contract.
Chambers USA has recognized Irena as a leading lawyer in intellectual property, where clients have described her as “excellent,” “knowledgeable, aggressive,” “knows the science forward and backward” and “an incredibly smart lawyer.” Benchmark Litigation named her one of the “Top 250 Women in Litigation” for the last eight years and a litigation star in intellectual property. Irena was also named to the Crain’s New York Business list of “Notable Women in Law.” She is also recognized as a leading lawyer by Legal 500. Irena writes and lectures widely on biopharma patent issues and biosimilar litigation. Irena also is frequently quoted on patent-related issues, including in the Washington Post, Financial Times, Nature Biotechnology, Bloomberg and Pink Sheet.
New York
With a Ph.D. in biology from MIT and the Whitehead Institute, where she was a NSF fellow, Irena represents plaintiffs and defendants in their most complex pharmaceutical and biotech patent cases. Over the last 20 years, pharmaceutical and biotechnology innovators have relied on Irena again and again for cases involving small molecules, biologics, recombinant DNA technology, gene therapy, gene editing, manufacturing processes, formulations and drug-eluting medical devices, including numerous multi-billion dollar cases involving many of the world’s best-selling drugs.
Irena has significant experience in litigation under the Hatch-Waxman Act (ANDA and 505(b)(2) actions) and the Biologics Price Competition and Innovation Act (BPCIA), as well as inter partes review (IPR) proceedings, license disputes and matters with parallel ex-U.S. litigation and proceedings in foreign patent offices. Irena also helps life sciences companies and organizations develop the law in the most important cases for the biopharma industry. She has been principal counsel on numerous amicus briefs to the United States Supreme Court and the Federal Circuit in key biopharma cases.
For plaintiffs, Irena has successfully defended generic challenges to patents protecting blockbuster medical therapies, including multi-billion dollar cancer, antiviral, diabetes and anti-psychotic drugs, including recently obtaining attorneys’ fees in a hard-fought ANDA action. She also represents innovators in biosimilar litigation from its outset, including in some of the first cases under the BPCIA involving antibodies. Irena also represents clients in innovator vs innovator disputes. For defendants, she defeated a $530 million claim of patent infringement of a competitor’s biotech patent, obtaining dismissal of all claims and discovery sanctions against the patent owner. In another high-stakes case, she obtained summary judgment of noninfringement and exclusion of plaintiff’s experts under Daubert as well as a full award of attorneys’ fees. A registered patent attorney, Irena also handles inter partes review (IPR) proceedings. For patent owners, she has obtained denial of IPR for patents protecting blockbuster drugs and has leveraged IPR for defendants to obtain freedom to operate.
Irena also coordinates U.S. proceedings with parallel ex-U.S. litigation and proceedings in foreign patent offices, recently obtaining freedom to operate for a biotech innovator’s gene therapy. She provides strategic counseling in biologics and pharmaceuticals and advises clients on their IP portfolios and transactions. Irena also represents clients in high-stakes license disputes involving biotech patents, and, in a dispute concerning the use of a recombinant protein as an enzyme replacement therapy, obtained one of the largest settlement awards over the life of the contract.
Chambers USA has recognized Irena as a leading lawyer in intellectual property, where clients have described her as “excellent,” “knowledgeable, aggressive,” “knows the science forward and backward” and “an incredibly smart lawyer.” Benchmark Litigation named her one of the “Top 250 Women in Litigation” for the last eight years and a litigation star in intellectual property. Irena was also named to the Crain’s New York Business list of “Notable Women in Law.” She is also recognized as a leading lawyer by Legal 500. Irena writes and lectures widely on biopharma patent issues and biosimilar litigation. Irena also is frequently quoted on patent-related issues, including in the Washington Post, Financial Times, Nature Biotechnology, Bloomberg and Pink Sheet.
Washington, D.C.
Chris has an active practice representing financial services entities in negotiating a wide variety of corporate transactions, including company M&A, asset purchases and critical vendor and other third-party relationships. His clients include banks, mortgage companies and servicers, marketplace and other lenders, fintech and emerging payments providers and other business entities in the financial services industry.
Chris’ M&A work emphasizes transactions that involve regulatory risks and concerns or novel structures at the forefront of industry trends. He also represents buyers and sellers of mortgage loans and other consumer lending assets, including interests such as mortgage servicing rights. He regularly negotiates many varieties of servicing and subservicing contracts.
He also advises clients on outsourcing, joint venture and bank partner agreements, particularly in the fintech and e-commerce arena, providing years of experience addressing “true lender” issues. He also advises clients on loan repurchase and indemnity matters as well as corporate governance and compliance matters.
His regulatory practice focuses on advising lenders and servicers on matters involving the Real Estate Settlement Procedures Act (RESPA), including affiliated business arrangements, portfolio retention transactions and vendor management issues.
Chris is recognized by Chambers USA for Fintech: Payments & Lending, which cited his capabilities “advising on regulatory compliance, commercial contracts matters and transactional work, with notable expertise handling M&A in the financial services sector.”
He was previously Co-Managing Partner and a member of the partner board at Buckley LLP. Before attending law school, he worked at the U.S. Department of State.
Washington, D.C.
Chris has an active practice representing financial services entities in negotiating a wide variety of corporate transactions, including company M&A, asset purchases and critical vendor and other third-party relationships. His clients include banks, mortgage companies and servicers, marketplace and other lenders, fintech and emerging payments providers and other business entities in the financial services industry.
Chris’ M&A work emphasizes transactions that involve regulatory risks and concerns or novel structures at the forefront of industry trends. He also represents buyers and sellers of mortgage loans and other consumer lending assets, including interests such as mortgage servicing rights. He regularly negotiates many varieties of servicing and subservicing contracts.
He also advises clients on outsourcing, joint venture and bank partner agreements, particularly in the fintech and e-commerce arena, providing years of experience addressing “true lender” issues. He also advises clients on loan repurchase and indemnity matters as well as corporate governance and compliance matters.
His regulatory practice focuses on advising lenders and servicers on matters involving the Real Estate Settlement Procedures Act (RESPA), including affiliated business arrangements, portfolio retention transactions and vendor management issues.
Chris is recognized by Chambers USA for Fintech: Payments & Lending, which cited his capabilities “advising on regulatory compliance, commercial contracts matters and transactional work, with notable expertise handling M&A in the financial services sector.”
He was previously Co-Managing Partner and a member of the partner board at Buckley LLP. Before attending law school, he worked at the U.S. Department of State.
New York
Nathaniel counsels banks, blockchain exchanges, cryptocurrency issuers, financial institutions, technology companies, money transmitters, online gaming platforms, payment processors, and private equity firms. His practice includes services related to anti-money laundering, data collection and processing, internal investigations and risks assessments, money transmitter licensing, blockchain token offerings, mergers and acquisitions, money transmitter licensing, venture capital financing activities, and general corporate matters.
Following law school, Nathaniel co-founded a legaltech company in Japan, and developed the initial machine learning models and a front end used for an initial product offering. Nathaniel has since leveraged his development experience to communicate with and advise blockchain and machine learning ventures. In addition, Nathaniel has also lectured at Peking University in China, teaching constitutional law and an introductory class on U.S. legal principles, giving Nathaniel a unique perspective into the Chinese market.
Prior to joining Orrick’s New York office, he was an associate at the firm's Tokyo office. In addition, prior to law school, Nathaniel served for four years in the Canadian Army as an enlisted soldier tasked to conduct armored reconnaissance.
New York
Nathaniel counsels banks, blockchain exchanges, cryptocurrency issuers, financial institutions, technology companies, money transmitters, online gaming platforms, payment processors, and private equity firms. His practice includes services related to anti-money laundering, data collection and processing, internal investigations and risks assessments, money transmitter licensing, blockchain token offerings, mergers and acquisitions, money transmitter licensing, venture capital financing activities, and general corporate matters.
Following law school, Nathaniel co-founded a legaltech company in Japan, and developed the initial machine learning models and a front end used for an initial product offering. Nathaniel has since leveraged his development experience to communicate with and advise blockchain and machine learning ventures. In addition, Nathaniel has also lectured at Peking University in China, teaching constitutional law and an introductory class on U.S. legal principles, giving Nathaniel a unique perspective into the Chinese market.
Prior to joining Orrick’s New York office, he was an associate at the firm's Tokyo office. In addition, prior to law school, Nathaniel served for four years in the Canadian Army as an enlisted soldier tasked to conduct armored reconnaissance.